Estimates Revisions Cerenis Therapeutics Liquidnet
Stocks
FR0012616852
Biotechnology & Medical Research
|
End-of-day quote
Liquidnet
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | - |
| 09-17 | Stifel Gets Carried Away With Abionyx Pharma |  |
| 09-11 | Abionyx Pharma Partners With ABL Diagnostics Division for Viral Safety Testing of CER-001 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
ABIONYX Pharma SA(ABNX)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
ABIONYX Pharma SA(ABNX)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
ABIONYX Pharma SA(ABNX)
EBIT
Dividend / Share (DPS)
Data source:
ABIONYX Pharma SA(ABNX)
Cash or Net Debt
- Stock Market
- Stocks
- ABNX Stock
- Stock
- Consensus Cerenis Therapeutics
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
